Abortion, Threatened, Pregnancy Trimester, First
Conditions
Keywords
Thromboelastometry, Vaginal Bleeding, Early Pregnancy
Brief summary
This study will use thromboelastometry in ED patients with vaginal bleeding, as well as healthy pregnant controls, to determine if abnormal results are associated with the presence of vaginal bleeding as well as later complications during pregnancy.
Detailed description
First, a case control study with samples collected from patients in the ED and OB clinic at Mount Sinai Hospital will be performed. Blood samples are being collected at time of study entry. Patient health history will be collected and blood samples will be tested using thromboelastometry in prospective fashion. Samples will be compared between groups. A prospective cohort will then be established using the subjects from the case control study. The purpose of this prospective cohort will be to collect outcomes of pregnancies to determine association with the initial thromboelastometry results.
Interventions
DIAGNOSTIC_TESTThromboelastometry testing
Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities
Sponsors
Icahn School of Medicine at Mount Sinai
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subjects will include pregnant women seen in the ED and OB clinic. The ED patients will include those seen for vaginal bleeding during pregnancy at less than 20 weeks gestation. OB Clinic patients will include those seen for first prenatal visit at which blood draw is performed, as long as this is also within 20 weeks estimated gestational age.
Exclusion criteria
* Patients with known histories of recurrent miscarriage, previously diagnosed thrombophilia, or other coagulopathy will be excluded. * Patients with ectopic pregnancies will also be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Clotting Firmness (MCF) | Day 1 | Thromboelastometry measurement of the Maximum Clot Firmness over the duration of the test. Performed as part of InTEM (response to ellagic acid) and ExTEM (response to tissue factor) measures. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clot formation time (CFT) | Day 1 | Time to thromboelastometry measurement of the angle between formation of clot at 0mm and 20mm of strength. Performed as part of InTEM (response to ellagic acid) and ExTEM (response to tissue factor) measures. |
| Clotting Time (CT) | Day 1 | Thromboelastometry measurement of the time to first clot formation. Performed as part of InTEM (response to ellagic acid) and ExTEM (response to tissue factor) measures. |
| Pregnancy Outcome | Within 40 weeks of enrollment at completion of pregnancy | Assessment of pregnancy outcome. Variable is treated as categorical and coded as spontaneous abortion, preterm labor, or term labor. |
| Number of Pregnancy Complications | Within 40 weeks of enrollment at completion of pregnancy | Number of Pregnancy complications as a composite including pre-eclampsia, postpartum hemorrhage, or other clotting or bleeding dysfunction such as pulmonary embolus or preterm bleeding episodes. |
Countries
United States
Outcome results
None listed